The US National Cancer Coalition (NCC) and Pfizer have joined forces to provide 10 million haemophilia medicines to patients in the developing world.

The ReFacto antihaemophilic factor (recombinant) therapy will be used for the treatment and prevention of bleeding for people with haemophilia A, who would otherwise have little access to adequate treatment.

In addition, the partnership believes these donations help to support the development of the infrastructure, which will create long-term value beyond the donation itself.

NCC President Robert Landry said that the organisation is dedicated to providing the resources and tools needed in the treatment and prevention of cancer, haemophilia, and other serious diseases and illnesses throughout the world.

“Product donations such as Pfizer’s are essential to address the needs of the patients and families that we serve globally,” Landry said.

Haemophilia A is a rare inherited blood-clotting disorder characteriaed by spontaneous haemorrhages or prolonged bleeding, typically into joints and soft tissue.